In a nutshell: Facts about the Dryvax study
The proposal for the study, titled "A Multicenter, Randomized Dose Response Study of the Safety, Clinical and Immune Responses of DryVax Vaccine Administered to Children 2 to 5 Years of Age," provides the following details:
• A total of 40 children would participate in Los Angeles and Cincinnati.
• Children would be administered a purified and lyophilized product prepared from lymph obtained from the skin of vaccinia-infected calves.
• Dryvax, produced by Wyeth Laboratories, is part of a limited, 15 million-dose stockpile that was prepared 20 years ago, discontinued in 1983, and now is in storage at the Centers for Disease Control and Prevention in Atlanta.
• Two studies have been conducted with the vaccine in adults, including undiluted Dryvax and 1:5, 1:10, and 1:100 vaccine dilutions.
• Some participants experienced systemic signs and symptoms including fever, headache, muscle aches, chills, nausea, fatigue, and rashes at remote sites. More than 2% of the 665 adult subjects with vesicle formation at varying periods after vaccination rated their headaches, muscle aches, and fatigue as severe.
• Serious adverse events were experienced by 12 subjects, including one case of severe headache with nausea lasting between days five and 14 post-vaccination, and a case of erythema around the vaccination site.
• A study of children receiving the smallpox vaccine in the early 1970s focused on primary percutaneous vaccination of 786 children between the ages of 1 and 9 years. Of 148 children who received Dryvax, eight developed satellite lesions, three developed erythema multiforme; and one developed a mild illness with generalized vesicular lesions.
The proposal for the study, A Multicenter, Randomized Dose Response Study of the Safety, Clinical and Immune Responses of DryVax Vaccine Administered to Children 2 to 5 Years of Age, provides the following details.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.